SAN DIEGO, CA April 4, 2007/MarketWire/– Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present its recently formed Cedar Therapeutics Inc. spin-out company at the C21 Bioventures Conference to be held at the Monterey Plaza Hotel and Spa, Monterey, CA May 22-24, 2007. Cedar Therapeutics was formed to develop novel, proprietary, and superior formulations for certain drugs recently or soon-to-be off-patent addressing a current total market in excess of $11 Billion and eligible for FDA 505(b)2 accelerated regulatory treatment using Aegis’ proprietary Intravail® and ProTek® advanced proprietary drug delivery and formulation technologies.
Information about the conference may be obtained from the following website: http://www.techvision.com/c21/pdf/c21_brochure.pdf
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.